ZIG
PTCT icon

Zuckerman Investment Group’s PTC Therapeutics PTCT Stock Holding History

Zuckerman Investment Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,421
Closed -$208K – 63
2018
Q3 		$208K Sell
4,421
-12,158
-73% -$503K 0.05% 58
2018
Q2 		$559K Sell
16,579
-57,104
-77% -$1.78M 0.13% 41
2018
Q1 		$1.99M Hold
73,683
– – 0.51% 32
2017
Q4 		$1.23M Buy
+73,683
New +$1.25M 0.31% 32

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Zuckerman Investment Group's PTCT Position: Q4 2018 in Review

Zuckerman Investment Group sold out of PTC Therapeutics (PTCT) in Q4 2018, closing a stake of 4,421 shares — an estimated $208K sold.

Zuckerman Investment Group first reported a position in PTCT in Q4 2017 and held it in 4 quarters. The position peaked at $1.99M in Q1 2018. 164 funds tracked by Wall St. Rank hold PTCT as of Q4 2018.

  • Zuckerman Investment Group reported no remaining PTC Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Zuckerman Investment Group sold 4,421 PTC Therapeutics shares in Q4 2018, an estimated $208K.
  • Zuckerman Investment Group first reported a position in PTC Therapeutics in Q4 2017 and held it in 4 quarters.
  • Zuckerman Investment Group's PTC Therapeutics position peaked at $1.99M in Q1 2018.
  • 164 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2018.

Based on Zuckerman Investment Group's 13F filing for Q4 2018, filed 13 Feb 2019.